Cited by 3,421Colorectal Cancer Treatments and StudiesColorectal Cancer Surgical TreatmentsIntraperitoneal and Appendiceal Malignancies

The DOI matches its Crossref record; 303 of the 309 references it cites were found in a registry or an index.

ESMO consensus guidelines for the management of patients with metastatic colorectal cancer

Open access

Van Cutsem, E., Cervantes, A., Adam, R., Sobrero, A., Van Krieken, J.H., Aderka, D., Aranda Aguilar, E., Bardelli, A., Benson, A., Bodoky, G., Ciardiello, F., D'Hoore, A., Diaz-Rubio, E., Douillard, J.-Y., Ducreux, M., Falcone, A., Grothey, A., Gruenberger, T., Haustermans, K., Heinemann, V., Hoff, P., Köhne, C.-H., Labianca, R., Laurent-Puig, P., Ma, B., Maughan, T., Muro, K., Normanno, N., Österlund, P., Oyen, W.J.G., Papamichael, D., Pentheroudakis, G., Pfeiffer, P., Price, T.J., Punt, C., Ricke, J., Roth, A., Salazar, R., Scheithauer, W., Schmoll, H.J., Tabernero, J., Taïeb, J., Tejpar, S., Wasan, H., Yoshino, T., Zaanan, A., Arnold, D.·2016·Annals of Oncology

DOI 10.1093/annonc/mdw235

Open this paper in CoChat — free account Open PDF

Abstract

Colorectal cancer (CRC) is one of the most common malignancies in Western countries. Over the last 20 years, and the last decade in particular, the clinical outcome for patients with metastatic CRC (mCRC) has improved greatly due not only to an increase in the number of patients being referred for and undergoing surgical resection of their localised metastatic disease but also to a more strategic approach to the delivery of systemic therapy and an expansion in the use of ablative techniques. This reflects the increase in the number of patients that are being managed within a multidisciplinary team environment and specialist cancer centres, and the emergence over the same time period not only of improved imaging techniques but also prognostic and predictive molecular markers. Treatment decisions for patients with mCRC must be evidence-based. Thus, these ESMO consensus guidelines have been developed based on the current available evidence to provide a series of evidence-based recommendations to assist in the treatment and management of patients with mCRC in this rapidly evolving treatment setting.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1093/annonc/mdw235

Cites

303 of 303 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D. M., Forman, D., & Bray, F. (2015) · International Journal of Cancer · doi:10.1002/ijc.29210 · Cited by 28,766
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012
Ferlay, J., Steliarova‐Foucher, E., Lortet‐Tieulent, J., Rosso, S., Coebergh, J. W. W., Comber, H., Forman, D., & Bray, F. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2012.12.027 · Cited by 5,243
The consensus molecular subtypes of colorectal cancer
Guinney, J., Dienstmann, R., Wang, X., de Reyniès, A., Schlicker, A., Soneson, C., Marisa, L., Roepman, P., Nyamundanda, G., Angelino, P., et al. (2015) · Nature Medicine · doi:10.1038/nm.3967 · Cited by 5,170
Self-citation
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
Bettegowda, C., Sausen, M., Leary, R. J., Kinde, I., Wang, Y., Agrawal, N., Bartlett, B. R., Wang, H., Luber, B., Alani, R. M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007094 · Cited by 5,067
Self-citation
Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer
Cunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., Bets, D., Mueser, M., Harstrick, A., Verslype, C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033025 · Cited by 5,035
Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
Van Cutsem, E., Köhne, C.-H., Hitre, E., Zaluski, J., Chang Chien, C.-R., Makhson, A., D'Haens, G., Pintér, T., Lim, R., Bodoky, G., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0805019 · Cited by 3,877
Self-citation
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer
de Gramont, A., Figer, A., Seymour, M., Homerin, M., Hmissi, A., Cassidy, J., Boni, C., Cortes-Funes, H., Cervantes, A., Freyer, G., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.16.2938 · Cited by 3,815
Self-citation
Clinical Score for Predicting Recurrence After Hepatic Resection for Metastatic Colorectal Cancer
Fong, Y., Fortner, J. G., Sun, R. L., Brennan, M. F., & Blumgart, L. H. (1999) · Annals of Surgery · doi:10.1097/00000658-199909000-00004 · Cited by 3,722

Show all 309 references

Research works printed but not linked: 6

Stintzing, 2013, Analysis of KRAS/NRAS and BRAF mutations in FIRE-3, Eur J Cancer, 49
Venook, 2014, J Clin Oncol, 32
Collettini, 2012, Percutaneous CT-guided high-dose brachytherapy (CT-HDRBT) ablation of primary and metastatic lung tumors in nonsurgical candidates, Rofo, 184, 316
Lenz, 2014, Ann Oncol, 25
Garcia Alfonso, 2014, Ann Oncol, 25
Cascinu, 2015, Eur J Cancer, 51

Sorted by citations

Items 701–800 of 1,003

Stromal Protein-Mediated Immune Regulation in Digestive Cancers
Gamradt, P., de la Fouchardière, C., & Hennino, A. (2021) · Cancers · doi:10.3390/cancers13010146 · Cited by 27
Review of Intra-Arterial Therapies for Colorectal Cancer Liver Metastasis
Kwan, J., & Pua, U. (2021) · Cancers · doi:10.3390/cancers13061371 · Cited by 25
Prognostic Value of the C-Reactive Protein/Albumin Ratio and Systemic Immune-Inflammation Index for Patients With Colorectal Liver Metastasis Undergoing Curative Resection
Deng, Y., Zhao, Y., Qin, J., Huang, X., Wu, R., Zhou, C., & Pan, Z. (2021) · Pathology & Oncology Research · doi:10.3389/pore.2021.633480 · Cited by 25
Pre-colectomy location and TNM staging of colon cancer by the computed tomography colonography: a diagnostic performance study
Zhou, Y., Han, Z., Dou, F., & Yan, T. (2021) · World Journal of Surgical Oncology · doi:10.1186/s12957-021-02215-4 · Cited by 25
Predictive Efficacy of MiR-125b-5p, MiR-17-5p, and MiR-185-5p in Liver Metastasis and Chemotherapy Response Among Advanced Stage Colorectal Cancer Patients
Sur, D. G., Bălăcescu, L., Cainap, S. S., Vișan, S., Pop, L., Burz, C. C., Havasi, A. D., Buiga, R., Cainap, C. I., Irimie, A., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.651380 · Cited by 25
Clinical impact of PET/MRI in oligometastatic colorectal cancer
Furtado, F., Weiss, K. E., Vangel, M. G., Clark, J. W., Cusack, J. C., Hong, T. S., Blaszkowsky, L. S., Wo, J. Y.-L., Striar, R., Umutlu, L., et al. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01494-8 · Cited by 25
NTRK fusions in colorectal cancer: clinical meaning and future perspective
Ratti, M., Grizzi, G., Passalacqua, R., Lampis, A., Cereatti, F., Grassia, R., & Hahne, J. C. (2021) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2021.1978070 · Cited by 24
Taiwan Society of Colon and Rectal Surgeons Consensus on mCRC Treatment
Chen, H., Ke, T., Huang, C., Jiang, J.-K., Chen, C., Hsieh, Y., Teng, H., Lin, B., Liang, Y., Su, Y., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.764912 · Cited by 24
The management of colorectal liver metastases amenable of surgical resection: How to shape treatment strategies according to clinical, radiological, pathological and molecular features
Germani, M. M., Borelli, B., Boraschi, P., Antoniotti, C., Ugolini, C., Urbani, L., Morelli, L., Fontanini, G., Masi, G., Cremolini, C., et al. (2022) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2022.102382 · Cited by 27
Yttrium-90 for colorectal liver metastasis - the promising role of radiation segmentectomy as an alternative local cure
Entezari, P., Gabr, A., Salem, R., & Lewandowski, R. J. (2022) · International Journal of Hyperthermia · doi:10.1080/02656736.2021.1933215 · Cited by 25
The role of interventional oncology in the treatment of colorectal cancer liver metastases
Tsitskari, M. (2019) · Annals of Gastroenterology · doi:10.20524/aog.2019.0338 · Cited by 25
Patterns and Timing of Recurrence following CRS and HIPEC in Colorectal Cancer Peritoneal Metastasis
Hassan, S., Malcomson, L., Soh, Y. J., Wilson, M. S., Clouston, H. W., O’Dwyer, S., Kochhar, R., & Aziz, O. (2022) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2022.07.019 · Cited by 25
Prognostic Factors of Survival in Patients with Peritoneal Metastasis from Colorectal Cancer
Mendoza‐Moreno, F., Díez‐Alonso, M., Matías‐García, B., Ovejero‐Merino, E., Gómez Sanz, R., Blázquez‐Martín, A., Quiroga‐Valcárcel, A., Vera-Mansilla, C., Molina, R., San‐Juan, A., et al. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11164922 · Cited by 25
Biweekly TAS-102 and bevacizumab as third-line chemotherapy for advanced or recurrent colorectal cancer: a phase II, multicenter, clinical trial (TAS-CC4 study)
Matsuoka, H., Yamada, T., Ohta, R., Yoshida, Y., Watanabe, T., Takahashi, M., Kosugi, C., Fukazawa, A., Kuramochi, H., Matsuda, A., et al. (2022) · International Journal of Clinical Oncology · doi:10.1007/s10147-022-02243-4 · Cited by 26
European expert panel consensus on the clinical management of BRAF-mutant metastatic colorectal cancer
Martinelli, E., Arnold, D., Cervantes, A. M. R., Stintzing, S., Cutsem, E. V., Tabernero, J. M., Taı̈eb, J., Wasan, H. S., & Ciardiello, F. (2023) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2023.102541 · Cited by 25
Self-citation
The anoikis-related gene signature predicts survival accurately in colon adenocarcinoma
Hu, G., Li, J., Zeng, Y., Liu, L., Yu, Z., Qi, X., Liu, K., & Yao, H. (2023) · Scientific Reports · doi:10.1038/s41598-023-40907-x · Cited by 26
Unravelling the pharmacologic opportunities and future directions for targeted therapies in gastro-intestinal cancers Part 1: GI carcinomas
Neuzillet, C., Rousseau, B., Kocher, H. M., Bourget, P., & Tournigand, C. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.02.028 · Cited by 25
Clinical validation of the next-generation sequencing-based Extended RAS Panel assay using metastatic colorectal cancer patient samples from the phase 3 PRIME study
Udar, N., Lofton–Day, C., Dong, J., Vavrek, D. A., Jung, A. S., Meier, K. M., Iyer, A., Slaughter, R. C., Gutekunst, K. A., Bach, B. A., et al. (2018) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-018-2688-3 · Cited by 24
Self-citation
Alternative splicing expands the prognostic impact of KRAS in microsatellite stable primary colorectal cancer
Eilertsen, I. A., Sveen, A., Strømme, J. M., Skotheim, R. I., Nesbakken, A., & Lothe, R. A. (2018) · International Journal of Cancer · doi:10.1002/ijc.31809 · Cited by 25
Hepatic arterial chemotherapy with raltitrexed and oxaliplatin versus standard chemotherapy in unresectable liver metastases from colorectal cancer after conventional chemotherapy failure (HEARTO): a randomized phase-II study
Ghiringhelli, F., Vincent, J., Bengrine-Lefèvre, L., Borg, C., Jouve, J. L., Loffroy, R., Guiu, B., Blanc, J., & Bertaut, A. (2019) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-019-02970-8 · Cited by 25
A comparison of regorafenib and fruquintinib for metastatic colorectal cancer: a systematic review and network meta-analysis
Zhu, J., Zhou, R., & binglan, Z. (2019) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-019-02964-6 · Cited by 26
GOLFIG Chemo-Immunotherapy in Metastatic Colorectal Cancer Patients. A Critical Review on a Long-Lasting Follow-Up
Caraglia, M., Correale, P., Giannicola, R., Staropoli, N., Botta, C., Pastina, P., Nesci, A., Caporlingua, N., Francini, E., Ridolfi, L., et al. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01102 · Cited by 25
Single-nucleotide variants, tumour mutational burden and microsatellite instability in patients with metastatic colorectal cancer: Next-generation sequencing results of the FIRE-3 trial
Stahler, A., Stintzing, S., von Einem, J. C., Westphalen, C. B., Heinrich, K., Krämer, N., Michl, M., Modest, D. P., von Weikersthal, L. F., Decker, T. W., et al. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2020.07.003 · Cited by 25
Self-citation
Ileal immune tonus is a prognosis marker of proximal colon cancer in mice and patients
Picard, M., Yonekura, S., Slowicka, K., Petta, I., Rauber, C., Routy, B., Richard, C., Iebba, V., Tidjani Alou, M., Becharef, S., et al. (2021) · Cell Death & Differentiation · doi:10.1038/s41418-020-00684-w · Cited by 24
Prognostic and Predictive Determinants of Colorectal Cancer: A Comprehensive Review
Cotan, H. T., Emilescu, R. A., Iaciu, C. I., Orlov-Slavu, C. M., Olaru, M., Popa, A. M., Jinga, M., Niţipir, C., Schreiner, O. D., & Ciobanu, R. C. (2024) · Cancers · doi:10.3390/cancers16233928 · Cited by 27
MNDA promotes immunosuppression in microsatellite instability-high colorectal cancer by facilitating PMN-MDSC infiltration via H3K18 lactylation
Zhang, X., Wang, W., Cai, X., Chen, X.-Q., Feng, Q., Yang, Q., Li, J.-B., Xiong, W., & Wu, T. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-07097-8 · Cited by 25
A comparison between 915 MHz and 2450 MHz microwave ablation systems for the treatment of small diameter lung metastases
Vogl, T. J., Roman, A., Nour-Eldin, N.-E. A., Schmidt, W. H., Bednarova, I., & Kaltenbach, B. (2018) · Diagnostic and Interventional Radiology · doi:10.5152/dir.2018.17017 · Cited by 24
Performance validation of an amplicon-based targeted next-generation sequencing assay and mutation profiling of 648 Chinese colorectal cancer patients
Wang, Y., Liu, H., Hou, Y., Zhou, X., Liang, L., Zhang, Z., Shi, H., Xu, S., Hu, P., Zheng, Z., et al. (2018) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-018-2359-4 · Cited by 24
Clinico-pathological associations and concomitant mutations of the RAS/RAF pathway in metastatic colorectal cancer
Isnaldi, E., Garuti, A., Cirmena, G., Scabini, S., Rimini, E., Ferrando, L., Lia, M., Murialdo, R., Tixi, L., Carminati, E., et al. (2019) · Journal of Translational Medicine · doi:10.1186/s12967-019-1879-2 · Cited by 24
A phase 1b study of the MET inhibitor capmatinib combined with cetuximab in patients with MET-positive colorectal cancer who had progressed following anti-EGFR monoclonal antibody treatment
Delord, J., Argilés, G., Fayette, J., Wirth, L. J., Kasper, S., Siena, S., Mesı́a, R., Berardi, R., Cervantes, A. M. R., Dekervel, J., et al. (2020) · Investigational New Drugs · doi:10.1007/s10637-020-00928-z · Cited by 24
Self-citation
The multidisciplinary management of oligometastases from colorectal cancer: a narrative review
Chandy, E., Saxby, H., Pang, J. W., & Sharma, R. A. (2020) · Annals of Palliative Medicine · doi:10.21037/apm-20-919 · Cited by 24
Current Landscape in Organic Nanosized Materials Advances for Improved Management of Colorectal Cancer Patients
Ginghină, O., Hudiță, A., Zaharia, C., Tsatsakis, A. M., Mezhuev, Y. O., Costache, M., & Gălățeanu, B. (2021) · Materials · doi:10.3390/ma14092440 · Cited by 24
Locoregional Therapies for Colorectal Cancer Liver Metastases: Options Beyond Resection
Uhlig, J., Lukovic, J., Dawson, L. A., Patel, R. A., Cavnar, M. J., & Kim, H. S. (2021) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_320519 · Cited by 25
The cancer angiogenesis co-culture assay: In vitro quantification of the angiogenic potential of tumoroids
Truelsen, S. L. B., Mousavi, N., Wei, H., Harvey, L., Stausholm, R., Spillum, E., Hagel, G., Qvortrup, K., Thastrup, M., Harling, H., et al. (2021) · PLoS ONE · doi:10.1371/journal.pone.0253258 · Cited by 26
Effects of locoregional radiotherapy in de novo metastatic nasopharyngeal carcinoma: A real-world study
Zeng, F., Lu, T., Xie, F., Chen, L., Zhang, L., Su, Y., Yu, Z., Xiao, Y., Ao, F., Li, G., et al. (2021) · Translational Oncology · doi:10.1016/j.tranon.2021.101187 · Cited by 24
Metastatic colorectal cancer and type 2 diabetes: prognostic and genetic interactions
Ottaiano, A., Circelli, L., Santorsola, M., Savarese, G., Fontanella, D., Gigantino, V., Mauro, A. D., Capuozzo, M., Zappavigna, S., Lombardi, A., et al. (2021) · Molecular Oncology · doi:10.1002/1878-0261.13122 · Cited by 25
Systematic review and non-inferiority meta-analysis of randomised phase II/III trials on S-1-based therapy versus 5-fluorouracil- or capecitabine-based therapy in the treatment of patients with metastatic colorectal cancer
Derksen, J. W. G., Smit, K. C., May, A. M., & Punt, C. J. A. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2022.02.004 · Cited by 24
Self-citation
Treatments after second progression in metastatic colorectal cancer: A pooled analysis of the TRIBE and TRIBE2 studies
Rossini, D., Germani, M. M., Lonardi, S., Pietrantonio, F., Dell’Aquila, E., Borelli, B., Allegrini, G., Maddalena, G., Randon, G., Marmorino, F., et al. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2022.04.019 · Cited by 25
Calmangafodipir for Prevention of Oxaliplatin-Induced Peripheral Neuropathy: Two Placebo-Controlled, Randomized Phase 3 Studies (POLAR-A/POLAR-M)
Pfeiffer, P., Lustberg, M. B., Näsström, J., Carlsson, S., Persson, A., Nagahama, F., Cavaletti, G., Glimelius, B. L. G., & Muro, K. (2022) · JNCI Cancer Spectrum · doi:10.1093/jncics/pkac075 · Cited by 24
Self-citation
Liver Venous Deprivation Versus Portal Vein Embolization Before Major Hepatectomy for Colorectal Liver Metastases: A Retrospective Comparison of Short- and Medium-Term Outcomes
Cassese, G., TROISI, R. I., Khayat, S., Benoudifa, B., Quénet, F., Guiu, B., & Panaro, F. (2022) · Journal of Gastrointestinal Surgery · doi:10.1007/s11605-022-05551-2 · Cited by 24
Predictive Factors for Adverse Event Outcomes After Transarterial Radioembolization with Yttrium-90 Resin Microspheres in Europe: Results from the Prospective Observational CIRT Study
Maleux, G. A., Albrecht, T., Arnold, D., Bargellini, I., Cianni, R., Helmberger, T. K., Kolligs, F. T., Munneke, G. J., Peynırcıoğlu, B., Sangro, B., et al. (2023) · CardioVascular and Interventional Radiology · doi:10.1007/s00270-023-03391-4 · Cited by 24
Self-citation
Advances in immunotyping of colorectal cancer
Wu, Y., Jing, Z., Qu, Z., Yang, X., & Han, S. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1259461 · Cited by 27
Treatment options for metastatic colorectal cancer in patients with liver dysfunction due to malignancy
Faugeras, L., Dili, A., Druez, A., Krug, B., Decoster, C., & D'Hondt, L. A. (2017) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.03.029 · Cited by 25
MiRNAs roles in the diagnosis, prognosis and treatment of colorectal cancer
Sur, D. G., Colceriu, M.-C., Sur, G., Aldea, C. O., Silaghi, C. N., Samaşcă, G., Lupan, I., Cainap, C. I., Burz, C. C., & Irimie, A. (2019) · Expert Review of Proteomics · doi:10.1080/14789450.2019.1659732 · Cited by 24
Secondary non-resectable liver tumors: A single-center living-donor and deceased-donor liver transplantation case series
Lerut, J. P., Iesari, S., Vandeplas, G., Fabbrizio, T., Ackenine, K., Núñez, M. E. I., Komuta, M., Coubeau, L., Ciccarelli, O., & Bonaccorsi‐Riani, E. (2019) · Hepatobiliary & pancreatic diseases international · doi:10.1016/j.hbpd.2019.08.005 · Cited by 24
The role of PIGF blockade in the treatment of colorectal cancer: overcoming the pitfalls
Macarulla, T. M., Montagut, C. O., Sánchez-Martín, F. J., Granja, M., Verdaguer, H., Sastre, J., & Tabernero, J. M. (2019) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2020.1677603 · Cited by 26
Self-citation
MR-guided microwave ablation in hepatic malignancies: clinical experiences from 50 procedures
Weiß, J., Winkelmann, M. T., Gohla, G., Kübler, J., Clasen, S., Nikolaou, K., & Hoffmann, R. (2020) · International Journal of Hyperthermia · doi:10.1080/02656736.2020.1750713 · Cited by 24
SLC25A18 has prognostic value in colorectal cancer and represses Warburg effect and cell proliferation via Wnt signaling.
Liang, L., Chen, Y., Yu, Y., Pan, W., Cui, Y., Xu, X., Peng, K., Liu, M., Rashid, K., Hou, Y., et al. (2020) · PubMed Central · Cited by 24
Detection of Somatic Mutations with ddPCR from Liquid Biopsy of Colorectal Cancer Patients
Zmrzljak, U. P., Košir, R., Krivokapić, Z., Radojkovic, D. P., & Nikolić, A. (2021) · Genes · doi:10.3390/genes12020289 · Cited by 26
Targeting signaling pathways with andrographolide in cancer therapy (Review)
Shaharudin, N. S., Singh, G. K. S., Kek, T., & Sultan, S. (2024) · Molecular and Clinical Oncology · doi:10.3892/mco.2024.2779 · Cited by 24
Analyzing postoperative complications in colorectal cancer surgery: a systematic review enhanced by artificial intelligence
Andraș, D., Lazăr, A. M., Crețoiu, D., Berghea, F., Georgescu, D. E., Grigorean, V. T., Iacoban, S. R., & Mastalier, B. S. M. (2024) · Frontiers in Surgery · doi:10.3389/fsurg.2024.1452223 · Cited by 23
Gut microbiota as a hidden modulator of chemotherapy: implications for colorectal cancer treatment
Sadeghloo, Z., & Sadeghi, A. (2025) · Discover Oncology · doi:10.1007/s12672-025-03574-0 · Cited by 24
TRIPLETE: a randomised phase III study of modified FOLFOXIRI plus panitumumab versus mFOLFOX6 plus panitumumab as initial therapy for patients with unresectable RAS and BRAF wild-type metastatic colorectal cancer
Borelli, B., Moretto, R., Lonardi, S., Bonetti, A. V., Antoniotti, C., Pietrantonio, F., Masi, G., Burgio, V., Marmorino, F., Salvatore, L., et al. (2018) · ESMO Open · doi:10.1136/esmoopen-2018-000403 · Cited by 25
Self-citation
Overexpression of Romo1 is an unfavorable prognostic biomarker and a predictor of lymphatic metastasis in non-small cell lung cancer patients
Kim, H. J., Jo, M. J., Kim, B. R., Kim, J. L., Jeong, Y. A., Na, Y. J., Park, S. H., Lee, S., Lee, D., Kim, B., et al. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s161587 · Cited by 23
Triplet Chemotherapy (FOLFOXIRI) Plus Bevacizumab Versus Doublet Chemotherapy (FOLFOX/FOLFIRI) Plus Bevacizumab in Conversion Therapy for Metastatic Colorectal Cancer: a Meta-Analysis
Shui, L., Wu, Y., Lin, H., Shui, P., Sun, Q., & Chen, X. (2018) · Cellular Physiology and Biochemistry · doi:10.1159/000492508 · Cited by 23
Changing outlook for colorectal liver metastasis resection in the elderly
Tufo, A., Dunne, D. F. J., Manu, N., Lacasia, C., Jones, L. E., Carino, N. D. L., Malik, H., Poston, G. J., & Fenwick, S. W. (2018) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2018.11.024 · Cited by 23
Safety of Aflibercept in Metastatic Colorectal Cancer: A Literature Review and Expert Perspective on Clinical and Real-World Data
Muro, K., Salinardi, T. C., Singh, A. R., & Macarulla, T. M. (2020) · Cancers · doi:10.3390/cancers12040844 · Cited by 23
Self-citation
Molecular Biomarkers according to Primary Tumor Location in Colorectal Cancer: Current Standard and New Insights
Renzi, G. D., Gaballo, G., Gazzaniga, P., & Nicolazzo, C. (2020) · Oncology · doi:10.1159/000510944 · Cited by 23
Perioperative Chemotherapy for Liver Metastasis of Colorectal Cancer
Chan, G. H. J., & Chee, C. E. (2020) · Cancers · doi:10.3390/cancers12123535 · Cited by 24
Current Status and Future Direction of Hepatic Radioembolisation
Alsultan, A. A., Braat, A. J. A. T., Smits, M. L. J., Barentsz, M. W., Bastiaannet, R., Bruijnen, R. C. G., de Keizer, B., de Jong, H. W. A. M., Lam, M. G. E. H., Maccauro, M., et al. (2020) · Clinical Oncology · doi:10.1016/j.clon.2020.12.003 · Cited by 23
Transarterial chemoembolization with doxorubicin-loaded beads for inoperable or recurrent colorectal cancer
Bi, Y., Shi, X., Ren, J., Yi, M., Han, X., & Song, M. (2021) · Abdominal Radiology · doi:10.1007/s00261-020-02877-w · Cited by 23
Phase II study of trifluridine/tipiracil plus bevacizumab by RAS mutation status in patients with metastatic colorectal cancer refractory to standard therapies: JFMC51-1702-C7
Takahashi, T., Yamazaki, K., Oki, E., Shiozawa, M., Mitsugi, K., Makiyama, A., Nakamura, M., Ojima, H., Kagawa, Y., Matsuhashi, N., et al. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100093 · Cited by 23
Self-citation
MRI Radiomics Signature as a Potential Biomarker for Predicting KRAS Status in Locally Advanced Rectal Cancer Patients
Zhang, Z., Shen, L., Wang, Y., Wang, J., Zhang, H., Xia, F., Wan, J., & Zhang, Z. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.614052 · Cited by 23
MSI-High RAS-BRAF wild-type colorectal adenocarcinomas with MLH1 loss have a high frequency of targetable oncogenic gene fusions whose diagnoses are feasible using methods easy-to-implement in pathology laboratories
Bocciarelli, C., Caumont, C., Samaison, L., Cariou, M., Aline-Fardin, A., Doucet, L., Roudié, J., Terris, B., Merlio, J., Marcorelles, P., et al. (2021) · Human Pathology · doi:10.1016/j.humpath.2021.05.006 · Cited by 23
Contrast Administration Impacts CT-Based Radiomics of Colorectal Liver Metastases and Non-Tumoral Liver Parenchyma Revealing the “Radiological” Tumour Microenvironment
Fiz, F., Costa, G., Gennaro, N., Bella, L. L., Boichuk, A., Sollini, M., Politi, L. S., Balzarini, L., Torzilli, G., Chiti, A., et al. (2021) · Diagnostics · doi:10.3390/diagnostics11071162 · Cited by 23
KRAS-G12C Mutation in One Real-Life and Three Population-Based Nordic Cohorts of Metastatic Colorectal Cancer
Osterlund, E., Ristimäki, A., Kytölä, S., Kuopio, T., Heervä, E., Muhonen, T., Halonen, P., Kallio, R., Soveri, L.-M., Sundström, J., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.826073 · Cited by 23
Self-citation
Updated Clinical Perspectives and Challenges of Chimeric Antigen Receptor-T Cell Therapy in Colorectal Cancer and Invasive Breast Cancer
Cao, Y., Efetov, S. K., He, M., Fu, Y., Beeraka, N. M., Zhang, J., Zhang, X., Bannimath, N., & Chen, K. (2023) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-023-00684-x · Cited by 24
Machine learning for predicting liver and/or lung metastasis in colorectal cancer: A retrospective study based on the SEER database
Guo, Z., Zhang, Z., Liu, L., Zhao, Y., Liu, Z., Zhang, C., Qi, H., Feng, J., Yang, C., Tai, W.-P., et al. (2024) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2024.108362 · Cited by 23
Efficacy and safety of nab-paclitaxel in patients with previously treated metastatic colorectal cancer: a phase II COLO-001 trial
Ducreux, M. P., Bennouna, J., Adenis, A., Conroy, T., Lièvre, A., Portales, F., Jeanes, J., Li, L., & Romano, A. (2016) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-016-3193-5 · Cited by 25
Self-citation
Future perspectives of circulating tumor DNA in colorectal cancer
Nadal, C., Winder, T. L., Gerger, A., & Tougeron, D. (2017) · Tumor Biology · doi:10.1177/1010428317705749 · Cited by 26
Japanese Society of Medical Oncology Clinical Guidelines: Molecular Testing for Colorectal Cancer Treatment, 4th edition
Ebi, H., Bando, H., Taniguchi, H., Sunakawa, Y., Okugawa, Y., Hatanaka, Y., Hosoda, W., Kumamoto, K., Nakatani, K., & Yamazaki, K. (2020) · Cancer Science · doi:10.1111/cas.14567 · Cited by 23
Validation of Metabolically Active Tumor Volume and Total Lesion Glycolysis as18F-FDG PET/CT–derived Prognostic Biomarkers in Chemorefractory Metastatic Colorectal Cancer
Woff, E., Hendlisz, A., Ameye, L., Garcia, C. A., Kamoun, T., Guiot, T., Paesmans, M., & Flamen, P. (2018) · Journal of Nuclear Medicine · doi:10.2967/jnumed.118.210161 · Cited by 23
“Market withdrawals” of medicines in Germany after AMNOG: a comparison of HTA ratings and clinical guideline recommendations
Staab, T. R., Walter, M., Nesurini, S. M., Dintsios, C., von der Schulenburg, J. M. G., Amelung, V. E., & Ruof, J. (2018) · Health Economics Review · doi:10.1186/s13561-018-0209-3 · Cited by 23
Non‐V600E BRAF mutations and EGFR signaling pathway in colorectal cancer
Osumi, H., Shinozaki, E., Wakatsuki, T., Suenaga, M., Ichimura, T., Ogura, M., Takahari, D., Ooki, A., Suzuki, T., Ota, Y., et al. (2019) · International Journal of Cancer · doi:10.1002/ijc.32320 · Cited by 23
Current Recommendations and Novel Strategies for the Management of Skin Toxicities Related to Anti-EGFR Therapies in Patients with Metastatic Colorectal Cancer
Annunziata, M. C., Stefano, A. D., Fabbrocini, G., Leo, S., Marchetti, P., Romano, M. C., & Romano, I. (2019) · Clinical Drug Investigation · doi:10.1007/s40261-019-00811-7 · Cited by 23
Clinical Application of Next-Generation Sequencing as A Liquid Biopsy Technique in Advanced Colorectal Cancer: A Trick or A Treat?
Kastrisiou, M., Zarkavelis, G., Pentheroudakis, G. E., & Magklara, A. (2019) · Cancers · doi:10.3390/cancers11101573 · Cited by 23
Self-citation
First-line trifluridine/tipiracil plus bevacizumab for unresectable metastatic colorectal cancer: SOLSTICE study design
André, T., Saunders, M. P., Kanehisa, A., Gandossi, E., Fougeray, R., Amellal, N., & Falcone, A. (2020) · Future Oncology · doi:10.2217/fon-2019-0786 · Cited by 23
Self-citation
Microwave Thermoablation of Colorectal Liver Metastases Close to Large Hepatic Vessels Under Pringle Maneuver Minimizes the “Heat Sink Effect”
Rhaiem, R., Kianmanesh, R., Minon, M., Tashkandi, A., Aghaei, A., Ledoux, G., Hoeffel, C., Bouché, O., Sommacale, D., & Piardi, T. (2020) · World Journal of Surgery · doi:10.1007/s00268-020-05379-4 · Cited by 23
Peri-operative chemotherapy for resectable colorectal lung metastasis: a systematic review and meta-analysis
Li, Y., & Qin, Y. (2020) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-020-03142-9 · Cited by 23
Factors That Influence Conversion to Resectability and Survival After Resection of Metastases in RAS WT Metastatic Colorectal Cancer (mCRC): Analysis of FIRE-3- AIOKRK0306
Modest, D. P., Heinemann, V., Folprecht, G., Denecke, T., Pratschke, J., Lang, H., Bemelmans, M. H. A., Becker, T., Rentsch, M., Seehofer, D., et al. (2020) · Annals of Surgical Oncology · doi:10.1245/s10434-020-08219-w · Cited by 23
Self-citation
Health-related quality of life in patients with RAS wild-type metastatic colorectal cancer treated with panitumumab-based first-line treatment strategy: A pre-specified secondary analysis of the Valentino study
Raimondi, A., Maïo, M. D., Morano, F., Corallo, S., Lonardi, S., Antoniotti, C., Rimassa, L., Bianchi, A. S., Tampellini, M., Ritorto, G., et al. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2020.04.048 · Cited by 23
Microvascular density assessed by CD31 predicts clinical benefit upon bevacizumab treatment in metastatic colorectal cancer: results of the PassionATE study, a translational prospective Phase II study of capecitabine and irinotecan plus bevacizumab followed by capecitabine and oxaliplatin plus bevacizumab or the reverse sequence in patients in mCRC
Bianconi, D., Herac, M., Posch, F., Schmeidl, M., Unseld, M., Kieler, M., Brettner, R., Müllauer, L., Riedl, J. M., Gerger, A., et al. (2020) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835920928635 · Cited by 23
Self-citation
What is the optimal number of neoadjuvant chemotherapy cycles for resectable colorectal liver oligometastases?
Chen, Q., Li, X., Zhao, J., Bi, X., Li, Z., Huang, Z., Zhang, Y., Zhou, J., Zhao, H., & Cai, J. (2021) · Annals of Translational Medicine · doi:10.21037/atm-20-4289 · Cited by 23
The Role of Percutaneous Ablation in the Management of Colorectal Cancer Liver Metastatic Disease
Filippiadis, D. K., Velonakis, G., Kelekis, A., & Sofocleous, C. T. (2021) · Diagnostics · doi:10.3390/diagnostics11020308 · Cited by 23
Monitoring levels of circulating cell‐free DNA in patients with metastatic colorectal cancer as a potential biomarker of responses to regorafenib treatment
Pastor, B., André, T., Henriques, J., Trouilloud, I., Tournigand, C., Jary, M., Mazard, T., Louvet, C., Azan, S., Bauer, A., et al. (2021) · Molecular Oncology · doi:10.1002/1878-0261.12972 · Cited by 24
Nomograms for estimating survival in patients with liver-only colorectal metastases: A retrospective study
Wu, Q., Wang, W., Huang, Y., Fang, S.-Y., & Guan, Y. (2018) · International Journal of Surgery · doi:10.1016/j.ijsu.2018.10.032 · Cited by 23
Circulating Tumor DNA Analysis in Colorectal Cancer: From Dream to Reality
Antoniotti, C., Pietrantonio, F., Corallo, S., de Braud, F., Falcone, A., & Cremolini, C. (2019) · JCO Precision Oncology · doi:10.1200/po.18.00397 · Cited by 24
Self-citation
Current treatment options in RAS mutant metastatic colorectal cancer patients: A meta-analysis of 14 randomized phase III trials
Stahler, A., Heinemann, V., Ricard, I., von Einem, J. C., Giessen-Jung, C., Westphalen, C. B., Michl, M., Heinrich, K., Miller-Phillips, L., Jelas, I., et al. (2020) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-020-03290-y · Cited by 21
Self-citation
RAS Mutation Conversion in Bevacizumab-Treated Metastatic Colorectal Cancer Patients: A Liquid Biopsy Based Study
Nicolazzo, C., Belardinilli, F., Vestri, A., Magri, V., De Renzi, G., De Meo, M., Caponnetto, S., Di Nicolantonio, F., Cortesi, E., Giannini, G., et al. (2022) · Cancers · doi:10.3390/cancers14030802 · Cited by 21
“, bevacizumab, aflibercept, and ramucirumab) [2].”
Multimodal Management of Colorectal Liver Metastases: State of the Art
Filoni, E., Musci, V., Rito, A. D., Inchingolo, R., Memeo, R., & Mannavola, F. (2024) · Oncology Reviews · doi:10.3389/or.2023.11799 · Cited by 22
Deciphering endocrine function of adipose tissue and its significant influences in obesity-related diseases caused by its dysfunction
Duan, F., Wu, J., Chang, J., Peng, H., Liu, Z., Liu, P., Han, X., Sun, T., Shang, D., Yang, Y., et al. (2024) · Differentiation · doi:10.1016/j.diff.2024.100832 · Cited by 27
Prognostic and predictive molecular biomarkers in colorectal cancer
Zhang, J., Zhu, H., Liu, W., Miao, J., Mao, Y., & Li, Q. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1532924 · Cited by 24
Clinical Usefulness of Tools to Support Decision-making for Palliative Treatment of Metastatic Colorectal Cancer: A Systematic Review
Engelhardt, E. G., Révész, D., Tamminga, H. J., Punt, C. J. A., Koopman, M., Onwuteaka-Philipsen, B. D., Steyerberg, E. W., Jansma, I. P., de Vet, H. C. W., & Coupé, V. M. H. (2017) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2017.06.007 · Cited by 22
Self-citation
Impact of primary tumour location and RAS/BRAF mutational status in metastatic colorectal cancer treated with first-line regimens containing oxaliplatin and bevacizumab: Prognostic factors from the AIO KRK0207 first-line and maintenance therapy trial
Hegewisch‐Becker, S., Nöpel‐Dünnebacke, S., Hinke, A., Graeven, U., Reinacher‐Schick, A., Hertel, J., Lerchenmuller, C. A., Killing, B., Depenbusch, R., Al‐Batran, S., et al. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.06.015 · Cited by 22
Self-citation
Targeting transcription factor TCF4 by γ-Mangostin, a natural xanthone
Krishnamachary, B., Subramaniam, D., Dandawate, P. R., Ponnurangam, S., Pugazhendhi, S., Ramamoorthy, P., Umar, S., Thomas, S. M., Dhar, A., Septer, S. S., et al. (2019) · Oncotarget · doi:10.18632/oncotarget.27159 · Cited by 22
Romo1 Inhibition Induces TRAIL-Mediated Apoptosis in Colorectal Cancer
Jo, M. J., Kim, B. G., Park, S. H., Kim, H. J., Jeong, S., Kim, B. R., Kim, J. L., Na, Y. J., Jeong, Y. A., Yun, H. K., et al. (2020) · Cancers · doi:10.3390/cancers12092358 · Cited by 22
Impact of Preanalytical Factors on the Measurement of Tumor Tissue Biomarkers Using Immunohistochemistry
Bagchi, A., Madaj, Z., Engel, K. B., Guan, P., Rohrer, D. C., Valley, D. R., Wolfrum, E., Feenstra, K., Roche, N., Hostetter, G. H., et al. (2021) · Journal of Histochemistry & Cytochemistry · doi:10.1369/0022155421995600 · Cited by 25
Identifying the optimal candidates for locoregional radiation therapy in patients with de novo metastatic nasopharyngeal carcinoma
Xu, H., Lu, L., Lu, T., Xu, Y., Zong, J., Huang, C., Lin, F., Zheng, Y., Lin, C., Lin, S., et al. (2021) · Head & Neck · doi:10.1002/hed.26726 · Cited by 22
Retrospective Study of Regorafenib Versus TAS-102 Efficacy and Safety in Chemorefractory Metastatic Colorectal Cancer (mCRC) Patients: A Multi-institution Real Life Clinical Data
Vitale, P., Zanaletti, N., Famiglietti, V., Falco, V. D., Cervantes, A. M. R., Roselló, S., Fenocchio, E., Milanesio, M. C., Lombardi, P., Ciardiello, D., et al. (2021) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2021.06.002 · Cited by 22
Self-citation
Virtual Biopsy for Diagnosis of Chemotherapy-Associated Liver Injuries and Steatohepatitis: A Combined Radiomic and Clinical Model in Patients with Colorectal Liver Metastases
Costa, G., Cavinato, L., Masci, C., Fiz, F., Sollini, M., Politi, L. S., Chiti, A., Balzarini, L., Aghemo, A., Tommaso, L. D., et al. (2021) · Cancers · doi:10.3390/cancers13123077 · Cited by 22

Authors: Van Cutsem, E., Cervantes, A., Adam, R., Sobrero, A., Van Krieken, J. H., Aderka, D., Aranda Aguilar, E., Bardelli, A., Benson, A., Bodoky, G., Ciardiello, F., D'Hoore, A., Diaz-Rubio, E., Douillard, J.-Y., Ducreux, M., Falcone, A., Grothey, A., Gruenberger, T., Haustermans, K., Heinemann, V., Hoff, P., Köhne, C.-H., Labianca, R., Laurent-Puig, P., Ma, B., Maughan, T., Muro, K., Normanno, N., Österlund, P., Oyen, W. J. G., Papamichael, D., Pentheroudakis, G., Pfeiffer, P., Price, T. J., Punt, C., Ricke, J., Roth, A., Salazar, R., Scheithauer, W., Schmoll, H. J., Tabernero, J., Taïeb, J., Tejpar, S., Wasan, H., Yoshino, T., Zaanan, A., & Arnold, D.
Affiliations: Universitat de València (ES)
Hôpital Paul-Brousse (FR)
Ospedale Policlinico San Martino (IT)
Tel Aviv University (IL)
University of Turin (IT)
Northwestern Medicine (US)
Unified Szent István and Szent László Hospital (HU)
University of Campania "Luigi Vanvitelli" (IT)
Institut de Cancérologie de l'Ouest (FR)
Université Paris-Saclay (FR)
University of Pisa (IT)
Mayo Clinic (US)
Krankenanstalt Rudolfstiftung der Stadt Wien (AT)
KU Leuven (BE)
Ludwig-Maximilians-Universität München (DE)
Universidade de São Paulo (BR)
Klinikum Oldenburg (DE)
Ospedale Papa Giovanni XXIII (IT)
Chinese University of Hong Kong (HK)
University of Oxford (GB)
Aichi Cancer Center (JP)
Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" (IT)
Institute of Cancer Research (GB)
Bank of Cyprus Oncology Center (CY)
University of Ioannina (GR)
Odense University Hospital (DK)
Queen Elizabeth Hospital (AU)
Amsterdam UMC Location University of Amsterdam (NL)
University Hospital Magdeburg (DE)
University Hospital of Geneva (CH)
Institut Català d'Oncologia (ES)
Comprehensive Cancer Center Vienna (AT)
Martin Luther University Halle-Wittenberg (DE)
Vall d'Hebron Hospital Universitari (ES)
Universitair Ziekenhuis Leuven (BE)
Imperial College Healthcare NHS Trust (GB)
National Cancer Center Hospital East (JP)
Hôpital Européen Georges-Pompidou (FR)
ORCID: Cervantes, A.
Adam, R.
Sobrero, A.
Bardelli, A.
Benson, A.
Bodoky, G.
Ciardiello, F.
Douillard, J.-Y.
Ducreux, M.
Falcone, A.
Grothey, A.
Gruenberger, T.
Haustermans, K.
Heinemann, V.
Hoff, P.
Labianca, R.
Ma, B.
Maughan, T.
Muro, K.
Normanno, N.
Oyen, W.J.G.
Papamichael, D.
Pentheroudakis, G.
Pfeiffer, P.
Price, T.J.
Punt, C.
Ricke, J.
Salazar, R.
Schmoll, H.J.
Tabernero, J.
Tejpar, S.
Wasan, H.
Yoshino, T.
Zaanan, A.
Arnold, D.
Venue: Annals of Oncology
Publisher: Elsevier BV
Published: 2016-08
Volume: 27
Issue: 8
Pages: 1386-1422
ISSN: 0923-7534 (ISSN-L)
DOI: 10.1093/annonc/mdw235
OpenAlex: W2470575266
Cited by: 3,421
References: 309
Citations by year: 2026: 199 · 2025: 236 · 2024: 297 · 2023: 364 · 2022: 481 · 2021: 518 · 2020: 444 · 2019: 365 · 2018: 279 · 2017: 189 · 2016: 39
FWCI: 155.89
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/open-access/userlicense/1.0/ (vor, 1191 d)
Locations: Annals of Oncology (publishedVersion)
PubMed (publishedVersion)
University of Southern Denmark Research Portal (University of Southern Denmark) (publishedVersion)
Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
Data Archiving and Networked Services (DANS) (submittedVersion)
CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion)
Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) (submittedVersion, other-oa)
Archivio Istituzionale della Ricerca - Università degli Studi della Campania "Luigi Vanvitelli" (submittedVersion)
Lirias (submittedVersion)
HighWire Press Open Archive (submittedVersion)
Pure Amsterdam UMC (submittedVersion)
Radboud Repository (Radboud University) (submittedVersion)
RISalud Institutional Health Repository of Andalucía (submittedVersion, other-oa)
Funders: Cancer Research UK (13363)
National Institute for Health and Care Research (11/100/50)
Topics: Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
Health Sciences › Medicine › Surgery › Intraperitoneal and Appendiceal Malignancies
Keywords: metastatic colorectal cancer, colorectal cancer, surgical resection of metastases, systemic therapy, multidisciplinary management, treatment decision-making, evidence-based recommendations
MeSH terms: Humans, Neoplasm Metastasis, Prognosis, Biomarkers, Tumor, Colorectal Neoplasms, Guidelines as Topic, Molecular Targeted Therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

ESMO consensus guidelines for the management of patients with metastatic colorectal cancer

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks